New Products In Brief
This article was originally published in The Gray Sheet
Executive SummarySynapse Biomedical’s NeuRx
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.